Erdosteine

Drug Profile

Erdosteine

Alternative Names: ALT 09; Asdigan; Biopulmin; Dostin; Dostol; Ectrin; Edirel; Erdomed; Erdopect; Erdos; Erdostin; Erdotin; Esteclin; Fluidasa; Flusten; KW 9144; Mucoflux; Mucofor; Mucotec; Mucothera; RV 144; Secresolv; Tusselin and Theovix; Tussol; Vectrine

Latest Information Update: 21 Jan 2016

Price : $50

At a glance

  • Originator Edmond Pharma
  • Developer Alitair Pharmaceuticals Inc; Edmond Pharma
  • Class Anti-inflammatories; Antibronchitics; Expectorants; Small molecules; Thioglycolates; Thiophenes
  • Mechanism of Action Antioxidants; Glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiectasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bronchitis
  • Phase III Chronic obstructive pulmonary disease
  • Preclinical Bronchiectasis

Most Recent Events

  • 18 Aug 2015 Phase II development is ongoing in the USA
  • 07 Jan 2014 Preclinical development for Bronchiectasis in USA (PO)
  • 07 Jan 2014 Erdosteine receives Orphan Drug status for Bronchiectasis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top